Drug intelligence / Profile preview

ivermectin + colchicine

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

A combination of ivermectin and colchicine that was investigated as a potential treatment for COVID-19. Ivermectin is an anti-parasitic medication that was hypothesized to reduce viral load, while colchicine is an anti-inflammatory agent that was thought to reduce inflammation in COVID-19 patients. Clinical trials have not shown beneficial effects of this combination over standard care in COVID-19 treatment.

Targets

GluCl (Glutamate-gated chloride channel)TUBB (Tubulin (alpha and beta subunits))GABAA (Gamma-aminobutyric acid receptor)

Beyond the preview

Go deeper on ivermectin + colchicine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivermectin + colchicine.

Explore the full profile